1 asset in Desmoplastic Melanoma
Therapeutic assets addressing Desmoplastic Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
Pembrolizumab Desmoplastic Melanoma | National Cancer Institute (NCI) | P2 | CCC (53) |